Season 3 - Ep.8: DAPT in 2025 - Optimal communication with patients

9 snips

Jan 30, 2025

Gilles Montalescot, a Professor of Cardiology at Pitié University Hospital in Paris, dives into vital topics, highlighting recent studies on dual antiplatelet therapy and its future in 2025. He discusses the prevalence of supine hypertension and its links to cardiovascular health, and the importance of personalized antiplatelet regimens. Montalescot emphasizes effective communication in patient care, focusing on transparency and empathy to alleviate anxiety. The dialogue also touches on innovative surgical techniques in cardiology, promising a transformative view of patient treatment.

Ask episode

AI Snips

Chapters

Books

Transcript

Episode notes

ADVICE

DAPT in Chronic Coronary Syndromes

For chronic coronary syndromes, prescribe aspirin lifelong and a short course of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel if a stent is needed.
No need for ticagrelor or prasugrel in these cases, as aspirin and clopidogrel suffice.

INSIGHT

DAPT Duration in ACS

In acute coronary syndromes (ACS), DAPT with aspirin and ticagrelor or prasugrel is necessary for all patients, regardless of treatment strategy.
Newer studies suggest that even in ACS, the DAPT duration can be shortened to three or even one month with similar ischemic outcomes and fewer bleedings.

ADVICE

DAPT in High Bleeding Risk Patients

For high bleeding risk patients, shorten DAPT duration as much as possible, often to one or three months.
Preferably continue with a P2Y12 antagonist like clopidogrel or ticagrelor after stopping aspirin, given its better safety and efficacy profile.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This episode covers:

Cardiology This Week: A concise summary of recent studies
Dual antiplatelet therapy in 2025
Optimal communication with patients
Snapshots

Host: Emer Joyce

Guests: Carlos Aguiar, Michelle Kittleson, Gilles Montalescot

Want to watch that episode? Go to: https://esc365.escardio.org/event/1798

Disclaimer

ESC TV Today is supported by Bristol Myers Squibb.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Emer Joyce, Michelle Kittleson and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo.

Gilles Montalescot has declared to have potential conflicts of interest to report: research funds for Action Groupe or honoraria from Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celecor, CSL Behring, Hexacath, Idorsia, Lilly, Novo Nordisk, Pfizer, SMT, Terumo.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.